Press release
Influenza Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Discover the latest drugs and treatment options in the Influenza Pipeline. Dive into DelveInsight's comprehensive report today! @ Influenza Pipeline Outlook [https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Influenza Pipeline Report
* In October 2024:- Pfizer- The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza. Influenza is a disease that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. The study vaccine is called Pandemic Influenza modRNA (pdmFlu) Vaccine.
* In October 2024:- ModernaTX Inc.- Phase 2, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 and Comparator Seasonal Influenza Vaccines in Healthy Adults. The main purpose of the study is to evaluate the safety, reactogenicity, and the humoral immunogenicity of mRNA-1010 and comparator influenza vaccines against homologous influenza A and B strains at Day 29.
* In October 2024:- Cidara Therapeutics Inc.- The purpose of this study is to select a dose of CD388 that is effective in preventing symptomatic laboratory-confirmed influenza infections, as compared to placebo, when administered as a single dose via 3 subcutaneous (SQ) injections to adult participants in stable health, and to evaluate the safety and tolerability of CD388, as compared to placebo.
* DelveInsight's Influenza pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Influenza treatment.
* The leading Influenza Companies such as Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others.
* Promising Influenza Therapies such as OVX836 480g, mRNA-1010, Oseltamivir, Baloxavir , and others.
Stay ahead with the most recent pipeline outlook for Influenza. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Influenza Treatment Drugs [https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Influenza Emerging Drugs
* mRNA-1010: Moderna
mRNA-1010 is a vaccine candidate that encodes for hemagglutinin (HA) glycoproteins of the four influenza strains recommended by the World Health Organization (WHO) for the prevention of influenza, including influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages. HA is a major influenza surface glycoprotein that is considered an important target to generate broad protection against influenza and is the primary target of currently available influenza vaccines. Currently, it is in Phase III stage of clinical trial evaluation to treat patients suffering from Seasonal Influenza.
* SAB-176: SAB Biotherapeutics
SAB-176 is a quadrivalent broadly neutralizing fully-human polyclonal antibody therapeutic candidate that leverages the human biological immune response in development for the treatment of hospitalized patients with severe seasonal influenza. The novel specifically targeted therapeutic generated from the company's proprietary technology, the DiversitAb Trademark platform, is designed to specifically bind to Type A and Type B influenza viruses. Pre-clinical data suggests that SAB-176 offers potentially broad protection against diverse influenza strains. A highly-potent, polyclonal antibody therapy for severe seasonal influenza, could potentially treat severely ill patients and provide protective antibodies for high-risk populations, such as the elderly and immune compromised.
* INNA-051: ENA Respiratory Pty Ltd
INNA-051 is a broad-spectrum antiviral immunomodulatory nasal spray under clinical development for pre- and post-exposure prophylaxis of respiratory viral infections in populations at risk of severe complications. Based on its mechanism of action and intended route of administration, INNA-051 has the potential to address several viral respiratory pathogens across multiple patient populations with a variety of co-morbid conditions. INNA-051 antiviral efficacy is currently evaluated in a Phase 2a influenza-challenge conducted in healthy volunteers.
* CODA-VAX H1N1: Codagenix
Codagenix has utilized a design platform to construct a live-attenuated, universal flu vaccine, CodaVax Trademark -H1N1. The vaccine enables presentation of conserved antigens of the wild-type virus, demonstrating universal potential in primate models and thus the potential to provide multi-season protection when developed into its final quadrivalent formulation. Currently, it is being evaluated in Phase I stage of clinical trial evaluation to treat Influenza virus infections.
* ALVR106: AlloVir
ALVR106 is an allogeneic, off-the-shelf, multi-virus specific VST therapy candidate designed to target diseases caused by the respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). In vitro data demonstrates that ALVR106 reactive cells have antiviral activity against each of the targeted viruses with minimal or no activity against non-virus-infected cells. This preclinical data supports the potential for antiviral benefit and safety of ALVR106 when administered to patients.
Explore groundbreaking therapies and clinical trials in the Influenza Pipeline. Access DelveInsight's detailed report now! @ New Influenza Drugs [https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Influenza pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous
Influenza Products have been categorized under various Molecule types such as
* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine
Unveil the future of Influenza Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Influenza Market Drivers and Barriers [https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Influenza Pipeline Report
* Coverage- Global
* Influenza Companies- Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others.
* Influenza Therapies- OVX836 480g, mRNA-1010, Oseltamivir, Baloxavir, and others
* Influenza Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Influenza Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Influenza Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Influenza Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Influenza: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Influenza - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* mRNA-1010: Moderna
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* INNA-051: ENA Respiratory Pty Ltd
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* CODA-VAX H1N1: Codagenix
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Influenza Key Companies
* Influenza Key Products
* Influenza- Unmet Needs
* Influenza- Market Drivers and Barriers
* Influenza- Future Perspectives and Conclusion
* Influenza Analyst Views
* Influenza Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=influenza-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Influenza Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers here
News-ID: 3692181 • Views: …
More Releases from ABNewswire
AllSafe IT Announces Thomas House Family Shelter as 2025 Make a Difference Grant …
AllSafe IT has selected Thomas House Family Shelter as the winner of its 2025 Make a Difference Grant, providing the Orange County-based nonprofit with a full year of managed IT services and strategic technology support. The grant will enable the organization to strengthen its technology infrastructure while continuing its mission to help families experiencing homelessness move toward independence and stability.
PASADENA, CA - January 8, 2026 - AllSafe IT is proud…
Local Logistics Firm 'Junk Removal Melbourne' Launches New Digital Platform to S …
Junk Removal Melbourne, a premier locally owned hauling and logistics provider, is proud to announce the official launch of its new website. The platform offers homeowners, property managers, and contractors in Viera, Palm Bay, and the entire Space Coast a streamlined way to schedule professional debris removal and access transparent, volume-based pricing.
The launch comes as demand for reliable and professional waste management services grows across the region. Unlike traditional hauling…
ADM Endeavors (OTCQB: ADMQ) Reports $5.3M Revenue, Expands Operations Supporting …
ADM Endeavors (OTCQB: ADMQ), a diversified direct marketing and value-added manufacturing company, continues to build momentum as its wholly owned subsidiary Just Right Products, Inc., delivers consistent revenue growth, expands into new markets, and significantly scales its operational facility footprint.
Recession-Resistant Revenue Base
Since 2010, ADM Endeavors' (OTCQB: ADMQ) has steadily grown a diversified and resilient customer base, generating more than $5.3 million in sales over the last reported 12 months. The…
Aether Holdings, Inc. (NASDAQ: ATHR) Is Building the AI-Fueled Investor Toolbox
Global markets are entering 2026 amid mixed macroeconomic signals, shifting investor sentiment, and continued debate around inflation, labor strength, and geopolitical risk. As information velocity increases and market narratives turn more quickly, investors are placing greater emphasis on how data is interpreted rather than simply how much data is available.
At the same time, advances in artificial intelligence and machine learning are influencing not only large-cap technology leaders but also a…
More Releases for Influenza
Multivalent Influenza Vaccines Market Advancing Influenza Prevention Strategies …
The "Multivalent Influenza Vaccines Market" research report represents major insights on the current growth dynamics as well as the primary revenue generation elements that are available in the Multivalent Influenza Vaccines industry along with various other factors over the predicted period 2024-2030. The report on the Multivalent Influenza Vaccines market is focusing on a series of parameters including top manufacturing strategies, industry share, prime opportunities, industrial channels, profit margin, etc.…
Influenza Diagnostics Market - Rapid Detection, Effective Protection: Influenza …
Newark, New Castle, USA: The "Influenza Diagnostics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Influenza Diagnostics Market: https://www.growthplusreports.com/report/influenza-diagnostics-market/8780
This latest report researches the industry structure, sales, revenue,…
Influenza Medication Market - Fight off the influenza virus with effective and r …
Newark, New Castle, USA: The "Influenza Medication Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Influenza Medication Market: https://www.growthplusreports.com/report/influenza-medication-market/7859
This latest report researches the industry structure, sales, revenue,…
Influenza Medication Market - Revolutionizing Flu Treatment: Innovating Advanced …
Newark, New Castle, USA - new report, titled Influenza Medication Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Influenza Medication market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Influenza Medication market. The report offers an overview of the market, which…
Influenza Vaccines Market - Empowering Strength, Nurturing Immunity: Innovating …
Newark, New Castle, USA - new report, titled Influenza Vaccines Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Influenza Vaccines market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Influenza Vaccines market. The report offers an overview of the market, which…
H1N1 Influenza (Swine Influenza) Market to Witness Growth by 2032, Estimates Del …
DelveInsight's "H1N1 Influenza (Swine Influenza) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of H1N1 Influenza (Swine Influenza), historical and forecasted epidemiology as well as the H1N1 Influenza (Swine Influenza) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The H1N1 Influenza (Swine Influenza) market report provides current treatment practices, emerging drugs, the market share of the individual therapies,…
